1. Kang DW, Han MK, Kim HJ, Sohn H, Kim BJ, Kwon SU, et al. Silent new ischemic lesions after index stroke and the risk of future clinical recurrent stroke.
Neurology. 2016;86:277-285.
2. Kang DW, Latour LL, Chalela JA, Dambrosia J, Warach S. Early ischemic lesion recurrence within a week after acute ischemic stroke.
Ann Neurol. 2003;54:66-74.
3. Nolte CH, Albach FN, Heuschmann PU, Brunecker P, Villringer K, Endres M, et al. Silent new DWI lesions within the first week after stroke.
Cerebrovasc Dis. 2012;33:248-254.
4. Braemswig TB, Usnich T, Albach FN, Brunecker P, Grittner U, Scheitz JF, et al. Early new diffusion-weighted imaging lesions appear more often in stroke patients with a multiple territory lesion pattern.
Stroke. 2013;44:2200-2204.
5. Kim WJ, Kim JH, Ko Y, Park JH, Yang MH, Jang MS, et al. Can early ischemic lesion recurrence on diffusion-weighted MRI affect functional outcome after acute ischemic stroke?
J Clin Neurol. 2010;6:19-26.
6. Kang DW, Lattimore SU, Latour LL, Warach S. Silent ischemic lesion recurrence on magnetic resonance imaging predicts subsequent clinical vascular events.
Arch Neurol. 2006;63:1730-1733.
8. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome.
Circulation. 1997;95:1-4.
9. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.
Lipids. 2010;45:907-914.
10. Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-rich lipoprotein cholesterol, small dense LDL cholesterol, and incident cardiovascular disease.
J Am Coll Cardiol. 2020;75:2122-2135.
11. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.
J Am Coll Cardiol. 2019;73:e285-e350.
12. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).
Clin Biochem. 2001;34:583-588.
13. Won KB, Heo R, Park HB, Lee BK, Lin FY, Hadamitzky M, et al. Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors.
Atherosclerosis. 2021;324:46-51.
16. Liu H, Liu K, Pei L, Li S, Zhao J, Zhang K, et al. Atherogenic index of plasma predicts outcomes in acute ischemic stroke.
Front Neurol. 2021;12:741754.
17. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment.
Stroke. 1993;24:35-41.
18. Hoshino T, Ishizuka K, Toi S, Mizuno T, Nishimura A, Wako S, et al. Prognostic role of hypertriglyceridemia in patients with stroke of atherothrombotic origin.
Neurology. 2022;98:e1660-e1669.
19. Frohlich J, Dobiásová M. Fractional esterification rate of cholesterol and ratio of triglycerides to HDL-cholesterol are powerful predictors of positive findings on coronary angiography.
Clin Chem. 2003;49:1873-1880.
20. Yoshida H, Kisugi R. Mechanisms of LDL oxidation.
Clin Chim Acta. 2010;411:1875-1882.
21. Labreuche J, Touboul PJ, Amarenco P. Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: a systematic review of the epidemiological studies.
Atherosclerosis. 2009;203:331-345.
22. Kim JS, Nah HW, Park SM, Kim SK, Cho KH, Lee J, et al. Risk factors and stroke mechanisms in atherosclerotic stroke: intracranial compared with extracranial and anterior compared with posterior circulation disease.
Stroke. 2012;43:3313-3318.